Metabolic Research

CagriSema

InvestigationalWeight & metabolic
5.1/10

BioHarmony verdict

Neutral

CagriSema is an investigational once-weekly amylin plus GLP-1 injectable that produced about 22.7% weight loss on-treatment in REDEFINE 1, per Garvey 2025 in NEJM. It is not yet approved and lost a head-to-head to tirzepatide.

Read full report

What is CagriSema?

CagriSema is an investigational once-weekly injection that combines two appetite drugs in a single dual-chamber pen: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 drug already sold as Wegovy and Ozempic. The idea is simple. Stack two different fullness signals and you get more weight loss than either alone. In the big Phase 3 obesity trial, people without diabetes lost about 22.7% of their body weight on-treatment over 68 weeks, per Garvey 2025. That is the biggest effect size I have scored in this incretin batch.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Two appetite pathways at once: GLP-1 satiety plus amylin satiety and gastric slowing

Safety watch-outs

  • Severe, persistent abdominal pain radiating to the back (possible pancreatitis): stop and seek care.
  • A neck lump, hoarseness, or trouble swallowing (possible thyroid signal): stop and consult a clinician.
  • Vomiting or diarrhea bad enough to cause dehydration: pause dosing and rehydrate, get medical help if it persists.
  • Personal or family history of medullary thyroid carcinoma or MEN 2: do not use, the class carries a thyroid C-cell warning.
  • Active gallbladder disease or signs of gallstones: consult a clinician before continuing.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for CagriSema yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalInvestigational
CompoundingNo FDA-approved fixed-dose combination; compounding eligibility is not established
Last checked2026-09-02
Next review2026-10-02 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.